Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307034 | 0.88 | FGFR1 (0.57) | FGFR1KDM4EHPGDMAPTPOLB | |
| SCHEMBL11679816 | 0.85 | FGFR1 (0.60) | FGFR1KDM4EHPGDMAPTPOLB | |
| SCHEMBL2939210 | 0.85 | FGFR1 (0.54) | FGFR1KDM4EHPGDMAPTPOLB | |
| SCHEMBL1539106 | 0.85 | HPGD (0.60) | FGFR1KDM4EHPGDMAPTPOLB | |
| SCHEMBL1306731 | 0.84 | FGFR1 (0.53) | FGFR1KDM4EHPGDMAPTPOLB | |
| SCHEMBL15822182 | 0.84 | FGFR1 (0.53) | FGFR1KDM4EHPGDMAPTPOLB | |
| SCHEMBL1306276 | 0.84 | FGFR1 (0.53) | FGFR1KDM4EHPGDMAPTPOLB | |
| SCHEMBL7814456 | 0.82 | FGFR1 (0.64) | FGFR1BRD4HDAC1 | |
| SCHEMBL17103068 | 0.82 | BRD4 (0.48) | FGFR1KDM4EHPGDMAPTPOLB | |
| SCHEMBL13668130 | 0.82 | FGFR1 (0.51) | FGFR1KDM4EHPGDMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
| CN-101355938-A | Pharmaceutical use of substituted amides | TRANSTECH PHARMA INC (US) | 2009-01-28 | — | — | CN | disclosed |
| EP-1945207-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | Transtech Pharma, Inc. (US) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007051811-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, CYP11B1, HSD11B2 | FGFR1 3010/4885KDM4E 2635/4885HPGD 27/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | FGFR1 3384/4885KDM4E 2708/4885HPGD 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.